Development, validation, and prognostic evaluation of LiverPRO for the prediction of significant liver fibrosis in primary care: a prospective cohort study
(2024)
Journal Article
Lindvig, K. P., Thorhauge, K. H., Hansen, J. K., Kjærgaard, M., Hansen, C. D., Johansen, S., Lyngbeck, E., Israelsen, M., Andersen, P., Bech, K. T., Torp, N., Schnefeld, H. L., Detlefsen, S., Möller, S., Graupera, I., Trelle, M. B., Antonsen, S., Harris, R., Kårhus, L. L., Bjørnsbo, K. S., …Thiele, M. (2025). Development, validation, and prognostic evaluation of LiverPRO for the prediction of significant liver fibrosis in primary care: a prospective cohort study. The Lancet Gastroenterology & Hepatology, 10(1), 55-67. https://doi.org/10.1016/S2468-1253%2824%2900274-7
Background
Clinically significant liver fibrosis is associated with future adverse events in patients with steatotic liver disease. We designed a software tool for detection of clinically significant liver fibrosis in primary care.
Methods
In th...
Read More about Development, validation, and prognostic evaluation of LiverPRO for the prediction of significant liver fibrosis in primary care: a prospective cohort study.